Location: USA
Founded in 2006
Publicly Traded
Develops and commercializes innovative eye therapies using proprietary hydrogel technology, including FDA-approved DEXTENZA for post-surgery ocular inflammation and pain, and treatments for glaucoma and retinal diseases.
"Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our robust product pipeline positions Ocular Therapeutix to become a leader in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current standard of care by developing sustained release alternatives."
Description Source: VentureRadar Research / Company Website
Keywords: Technology; Major Pharmaceuticals; Life Sciences; Medical Device; Biotechnology; Ophthalmology; Biotech; Drug Delivery; Formulation; Delivery
Updates
All
Funding
Insight
Grant
Award
Conference
Competition
Research
Website Traffic Trend
Business Insight
01 Sep 2022
Website traffic has increased in the past 3 months, up from a ranking of 671,134 to 185,963.
Source:
Data from alexa.com
Website Traffic Trend
Business Insight
01 Mar 2022
Website traffic has decreased in the past 3 months, down from a ranking of 160,754 to 319,638.
Source:
Data from alexa.com
Website Traffic Trend
Business Insight
01 Oct 2020
Website traffic has increased in the past 3 months, up from a ranking of 896,389 to 160,754.
Source:
Data from alexa.com
Website Traffic Trend
Business Insight
01 Aug 2020
Website traffic has increased in the past 3 months, up from a ranking of 896,389 to 244,861.
Source:
Data from alexa.com
The Ophthalmology Innovation Summit (2019)
Conference
10 Oct 2019
One of Presenting Companies
Source: ois.net
Website Traffic Trend
Business Insight
01 Jun 2019
Website traffic has decreased in the past 3 months, down from a ranking of 611,897 to 896,389.
Source:
Data from alexa.com
The Ophthalmology Innovation Summit (2017)
Conference
09 Nov 2017
One of Presenting Companies
Source: ois.net
Venture-funding News
Equity Funding
10 Jun 2013
Ocular Therapeutix Secures Additional financing in Series D Round
Source: finsmes.com
Venture-funding News
Equity Funding
29 Jan 2013
Ocular Therapeutix Closes $23.8M Series D Financing
Source: finsmes.com
Venture-funding News
Equity Funding
03 Feb 2011
Ocular Therapeutix Closes $14M Series D Financing
Source: finsmes.com
View Funding Rounds for Keywords: Technology; Major Pharmaceuticals; Life Sciences; Medical Device; Biotechnology; Ophthalmology; Biotech; Drug Delivery; Formulation; Delivery
Funding Signals
VENTURE FUNDED
Polaris PartnersPolaris Venture PartnersVenture-funding News
Export Similar Companies
Similar Companies
| Company | Country | Status | Description |
|---|---|---|---|
| EyePointPharmaceuticals | USA | PubliclyTraded | pSivida is a leading provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems. Our proven proprietary technologies... |
| KioraPharmaceuticals(fkaEyeGatePharmaceuticals) | USA | PubliclyTraded | Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. KIO-101 is a... |
| KalaPharmaceuticals | USA | PubliclyTraded | Kala Pharmaceuticals, Inc. is advancing innovative treatments for ocular diseases addressing significant needs in both front and back of the eye based on the company's proprietary... |
| MatiTherapeutics | USA | PrivatelyHeld | Headquartered in Austin, Texas, Mati Therapeutics is developing a non-invasive sustained drug delivery platform to treat ocular diseases, in particular glaucoma. Four of the... |
| Eyenovia | USA | PubliclyTraded | Eyenovia is a clinical stage, ophthalmic biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry... |
| Novaliq | Germany | PrivatelyHeld | Novaliq is a drug delivery company focusing on difficult to dissolve substances for ophthalmic and dermatological applications. Novaliq’s patented semifluorinated alkanes (SFAs)... |
| {cn} | {cc} | {cs} | {cd} ... | |
|
You have reached your Free Usage LimitAccess Full Search Results with a Business Account or On Demand Pass Upgrade Now | ||||
| Free limit reached | n/a | Private | 100 | Upgrade |
| Upgrade for full access | n/a | Upgrade | 35 | Upgrade |
| Upgrade | n/a | n/a | 72 | Upgrade |
Related Top Ranked Companies Lists
TechnologyMajor PharmaceuticalsLife SciencesMedical DeviceBiotechnologyOphthalmologyBiotechDrug DeliveryFormulationDelivery
VentureRadar Score
Is this your company?
Claim this profile and
update details for free
Sub-Scores
SocialProof
790
WebsiteTraffic
850
AutoAnalystScore
680
Popularityon VentureRadar
994
Website Popularity
| |||||||||||
| Open PageRank: 1,487,239 | ocutx.com | |||||||||||
Auto Analyst Score
| 68 | ||||
| | ||||
| Auto Analyst Score: 68 | ocutx.com |
VentureRadar Popularity
| High | ||||
| VentureRadar Popularity: High The popularity score combines profile views, clicks and the number of times the company appears in search results. | ||||
Upgrade for full access
Upgrade to a paid plan for: Full Access from$60.00 per monthYou have reached your free usage limit for today.
Upgrade Now
Your VentureRadar Business account is now active and
your account information has been sent to your email address.
or
By continuing, you agree to VentureRadar's Terms of Service, Privacy Policy and Cookie Policy.
